Lack of involvement of alpha-synuclein in unconditioned anxiety in mice

Behavioural Brain Research

Volumn 209, Issue 2, 2010, Pages 234-240

  Peña Oliver, Yolanda ^a   Buchman, Vladimir L ^b   Stephens, David N ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Alpha synuclein; Anxiety; Elevated plus maze; Light dark box; Mice; Open field

Indexed keywords

ALPHA SYNUCLEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; EMOTIONALITY; KNOCKOUT MOUSE; LIGHT DARK CYCLE; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; WILD TYPE;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; EXPLORATORY BEHAVIOR; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURONS;

EID: 77649236543     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.01.049     Document Type: Article

References (47)

1. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
2. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 (1998) 106-108
3. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
4. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
5. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95 (1998) 6469-6473
6. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55 (2004) 164-173
7. Peng X., Tehranian R., Dietrich P., Stefanis L., and Perez R.G. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118 (2005) 3523-3530
8. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22 (2002) 3090-3099
9. Fountaine T.M., and Wade-Martins R. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 85 (2007) 351-363
10. Lee F.J., Liu F., Pristupa Z.B., and Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15 (2001) 916-926
11. Wersinger C., and Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 340 (2003) 189-192
12. Boyer F., and Dreyer J.L. Alpha-synuclein in the nucleus accumbens induces changes in cocaine behaviour in rats. Eur J Neurosci 26 (2007) 2764-2776
13. Mash D.C., Ouyang Q., Pablo J., Basile M., Izenwasser S., Lieberman A., et al. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J Neurosci 23 (2003) 2564-2571
14. Qin Y., Ouyang Q., Pablo J., and Mash D.C. Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. Neuroreport 16 (2005) 1489-1493
15. Brenz Verca M.S., Bahi A., Boyer F., Wagner G.C., and Dreyer J.L. Distribution of alpha- and gamma-synucleins in the adult rat brain and their modification by high-dose cocaine treatment. Eur J Neurosci 18 (2003) 1923-1938
16. Fornai F., Lenzi P., Ferrucci M., Lazzeri G., di Poggio A.B., Natale G., et al. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res Bull 65 (2005) 405-413
17. Liang T., Spence J., Liu L., Strother W.N., Chang H.W., Ellison J.A., et al. alpha-Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcohol-preferring and -nonpreferring rats. Proc Natl Acad Sci USA 100 (2003) 4690-4695
18. Bonsch D., Reulbach U., Bayerlein K., Hillemacher T., Kornhuber J., and Bleich S. Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism. Biol Psychiatry 56 (2004) 984-986
19. Bonsch D., Greifenberg V., Bayerlein K., Biermann T., Reulbach U., Hillemacher T., et al. Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. Alcohol Clin Exp Res 29 (2005) 763-765
20. Marinus J., Leentjens A.F., Visser M., Stiggelbout A.M., and van Hilten J.J. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol 25 (2002) 318-324
21. Nuti A., Ceravolo R., Piccinni A., Dell'Agnello G., Bellini G., Gambaccini G., et al. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol 11 (2004) 315-320
22. Richard I.H. Anxiety disorders in Parkinson's disease. Adv Neurol 96 (2005) 42-55
23. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15 (2000) 669-677
24. Walsh K., and Bennett G. Parkinson's disease and anxiety. Postgrad Med J 77 (2001) 89-93
25. Morris E.P., Stewart S.H., and Ham L.S. The relationship between social anxiety disorder and alcohol use disorders: a critical review. Clin Psychol Rev 25 (2005) 734-760
26. Terra M.B., Barros H.M., Stein A.T., Figueira I., Jorge M.R., Palermo L.H., et al. Social anxiety disorder in 300 patients hospitalized for alcoholism in Brazil: high prevalence and undertreatment. Compr Psychiatry 47 (2006) 463-467
27. Chiavegatto S., Izidio G.S., Mendes-Lana A., Aneas I., Freitas T.A., Torrao A.S., et al. Expression of alpha-synuclein is increased in the hippocampus of rats with high levels of innate anxiety. Mol Psychiatry 14 (2009) 894-905
28. George S., van den Buuse M., San Mok S., Masters C.L., Li Q.X., and Culvenor J.G. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 210 (2008) 788-792
29. Siegmund A., Langnaese K., and Wotjak C.T. Differences in extinction of conditioned fear in C57BL/6 substrains are unrelated to expression of alpha-synuclein. Behav Brain Res 157 (2005) 291-298
30. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132 (1997) 107-124
31. Podhorna J., and Brown R.E. Strain differences in activity and emotionality do not account for differences in learning and memory performance between C57BL/6 and DBA/2 mice. Genes Brain Behav 1 (2002) 96-110
32. Walsh R.N., and Cummins R.A. The Open-Field Test: a critical review. Psychol Bull 83 (1976) 482-504
33. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92 (1987) 180-185
34. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24 (1986) 525-529
35. Stephens D.N., Meldrum B.S., Weidmann R., Schneider C., and Grutzner M. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity?. Psychopharmacology (Berl) 90 (1986) 166-169
36. Rodgers R.J., and Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21 (1997) 801-810
37. Costall B., Jones B.J., Kelly M.E., Naylor R.J., and Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32 (1989) 777-785
38. Crawley J., and Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13 (1980) 167-170
39. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
40. Robertson D.C., Schmidt O., Ninkina N., Jones P.A., Sharkey J., and Buchman V.L. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem 89 (2004) 1126-1136
41. Senior S.L., Ninkina N., Deacon R., Bannerman D., Buchman V.L., Cragg S.J., et al. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27 (2008) 947-957
42. Specht C.G., and Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neuroscience 2 (2001) 11-19
43. Jakes R., Spillantini M.G., and Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 345 (1994) 27-32
44. Nakajo S., Tsukada K., Omata K., Nakamura Y., and Nakaya K. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 217 (1993) 1057-1063
45. Chandra S., Fornai F., Kwon H.B., Yazdani U., Atasoy D., Liu X., et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 101 (2004) 14966-14971
46. Kuhn M., Haebig K., Bonin M., Ninkina N., Buchman V.L., Poths S., et al. Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics 8 (2007) 71-81
47. Clement Y., Calatayud F., and Belzung C. Genetic basis of anxiety-like behaviour: a critical review. Brain Res Bull 57 (2002) 57-71